/
FTRE
$17.52-$0.13 (-0.74%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.7B
95M shares
52-week range
$4.36 – $18.67
92% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.41%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-19.32
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $2.58B | $3.06B | $2.84B | $2.84B | $2.70B | $2.72B |
| Cost of revenue | $2.09B | $2.45B | $2.11B | $2.25B | $2.16B | $2.30B |
| Gross profit | $489.1M | $604.4M | $724.4M | $590.6M | $534.2M | $425.8M |
| Gross margin | 19.0% | 19.8% | 25.5% | 20.8% | 19.8% | 15.6% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | −$314.2M | $114.3M | $187.1M | $32.0M | −$161.9M | −$30.6M |
| EBITDA | $221.5M | $302.9M | $280.8M | $137.2M | −$64.3M | −$813.6M |
| Net income | −$359.2M | $98.0M | $186.2M | −$25.2M | −$328.5M | −$986.2M |
| Net margin | -13.9% | 3.2% | 6.6% | -0.9% | -12.2% | -36.2% |
| EPS (diluted) | -4.06 | 1.11 | 2.11 | -0.04 | -3.67 | -10.81 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.6B | $0.81 | $0.74–$0.89 | 7 |
| 2027 | $2.7B | $1.02 | $0.80–$1.24 | 7 |
| 2028 | $2.8B | $1.27 | $-0.58–$4.60 | 4 |
| 2029 | $3.0B | $1.79 | $1.77–$1.82 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Fortrea Holdings Inc. Common Stock
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
www.fortrea.com- Employees
- 14,000
- IPO / List date
- Jun 16, 2023
- HQ
- DURHAM, NC
Held by traders on TradeandTell
No one on the platform currently holds FTRE.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 1,432,709 | $13.5M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded FTRE yet.
